Sunho Biologics Inc (2898.HK) Q3 2024 Earnings Report

Sunho Biologics reported QQ3 2024 results ending 2024-09-30 with continued operating losses driven by ongoing R&D investment and limited revenue visibility. Key metrics show an operating loss of 24.21 million CNY and a net loss of 21.94 million CNY for the quarter, with EBITDA of -22.53 million CNY. Revenue for QQ3 2024 is not disclosed in the reported data, and the company continues to incur meaningful R&D outlays (16.70 million CNY) alongside selling, general, and administrative costs (7.50 million CNY). Despite the negative near-term profitability, Sunho Biologics maintains a strong liquidity position: total cash and equivalents plus short-term investments stand at approximately 457.28 million CNY, with net debt of -37.80 million CNY, indicating net cash. The balance sheet shows a highly liquid profile (current ratio of 11.17x and quick ratio of 11.15x) and a substantial equity base (about 511.94 million CNY), underscoring a robust funding runway to support its pipeline and preclinical programs. The reported period reflects continued R&D intensity as the company advances its antibody and immunocytokine programs toward later-stage evaluation. With no near-term revenue milestones disclosed, the investment narrative centers on clinical milestones, potential partnerships, and the ability to preserve capital while progressing multiple initiatives in oncology and autoimmune indications. Management commentary from the QQ3 call is not captured in the provided data; as such, the outlook hinges on trial progress, potential licensing opportunities, and the broader funding environment for Chinese biotech peers.